ArticleBMC cancer2005
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.
Article in BMC cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 71 citations in OpenAlex.
- Proteome profiling reveals early diagnostic biomarker candidates for colorectal cancer.BMC cancer · 2026Article
- Carbonic Anhydrase Inhibitors in Oncology.Sub-cellular biochemistry · 2026Review
- Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients.Journal of molecular medicine (Berlin, Germany) · 2025Article
- The reducing effect of TNF-α on carbonic anhydrase III gene expression in colon carcinoma and osteosarcoma cells.Cytotechnology · 2025Article
- Different hypoxic response of humanTurkish journal of biology = Turk biyoloji dergisi · 2025Article
- Panomics reveals patient individuality as the major driver of colorectal cancer progression.Journal of translational medicine · 2023Article
- Extended transcriptome analysis reveals genome-wide lncRNA-mediated epigenetic dysregulation in colorectal cancer.Computational and structural biotechnology journal · 2020Article
- Carbonic anhydrases as disease markers.Expert opinion on therapeutic patents · 2019Review
- Carbonic Anhydrases: Role in pH Control and Cancer.Metabolites · 2018Review
- Article
- Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq.Biochemical pharmacology · 2017Article
- Identification of differentially expressed genes and their upstream regulators in colorectal cancer.Cancer gene therapy · 2017Article
- Structure activity study of carbonic anhydrase IX: Selective inhibition with ureido-substituted benzenesulfonamides.European journal of medicinal chemistry · 2017Article
- A Novel Stopped-Flow Assay for Quantitating Carbonic-Anhydrase Activity and Assessing Red-Blood-Cell Hemolysis.Frontiers in physiology · 2017Article
- Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas.World journal of gastroenterology · 2016Article
- Article
- [Analysis of differentially expressed proteome in urine from non-small cell lung cancer patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors.BioMed research international · 2015Review
- Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII.Topics in anti-cancer research · 2015Article
- Acidic extracellular microenvironment and cancer.Cancer cell international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbonic anhydrase (CA) isozymes may have an important role in cancer development. Some isozymes control pH homeostasis in tumors that appears to modulate the behaviour of cancer cells. CA XIII is the newest member of the CA gene family. It is a cytosolic isozyme which is expressed in a number of normal tissues. The present study was designed to investigate CA XIII expression in prospectively collected colorectal tumor samples.
methodsBoth neoplastic and normal tissue specimens were obtained from the same patients. The analyses were performed using CA XIII-specific antibodies and an immunohistochemical staining method. For comparison, the tissue sections were immunostained for other cytosolic isozymes, CA I and II.
resultsThe results indicated that the expression of CA XIII is down-regulated in tumor cells compared to the normal tissue. The lowest signal was detected in carcinoma samples. This pattern of expression was quite parallel for CA I and II.
conclusionThe down-regulation of cytosolic CA I, II and XIII in colorectal cancer may result from reduced levels of a common transcription factor or loss of closely linked CA1, CA2 and CA13 alleles on chromosome 8. Their possible role as tumor suppressors should be further evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.